Elevance Health Files 8-K
Ticker: ELV · Form: 8-K · Filed: Sep 15, 2025 · CIK: 1156039
Sentiment: neutral
Topics: 8-K, disclosure, regulatory-filing
TL;DR
ELEVANCE HEALTH FILED AN 8-K ON 9/15 FOR AN EVENT ON 9/8 - DETAILS PENDING
AI Summary
Elevance Health, Inc. filed an 8-K on September 15, 2025, reporting an event that occurred on September 8, 2025. The filing indicates "Other Events" and "Financial Statements and Exhibits" as key items, with no specific financial figures or new material events detailed in the provided text.
Why It Matters
This 8-K filing from Elevance Health signals a regulatory update or disclosure, though the specific nature of the event on September 8, 2025, requires further examination of the full document.
Risk Assessment
Risk Level: low — The filing is a standard 8-K disclosure without immediate indication of significant negative events or financial impact.
Key Numbers
- 20250915 — Filing Date (Date the 8-K was officially submitted to the SEC.)
- 20250908 — Event Date (The earliest date of the event(s) being reported in the 8-K.)
Key Players & Entities
- Elevance Health, Inc. (company) — Registrant
- Indiana (jurisdiction) — State of incorporation
- Anthem, Inc. (company) — Former company name
- WELLPOINT, INC (company) — Former company name
FAQ
What specific 'Other Events' are being reported by Elevance Health?
The provided text does not specify the 'Other Events'; the full 8-K filing would contain this information.
What are the 'Financial Statements and Exhibits' referenced in the filing?
The filing indicates that financial statements and exhibits are part of the report, but their specific content is not detailed in the provided excerpt.
When did Elevance Health, Inc. change its name from Anthem, Inc.?
Elevance Health, Inc. changed its name from Anthem, Inc. on December 2, 2014 (20141202).
What is Elevance Health's principal executive office address?
The principal executive offices are located at 220 Virginia Avenue, Indianapolis, IN 46204.
What is the Commission File Number for Elevance Health?
The Commission File Number for Elevance Health, Inc. is 001-16751.
Filing Stats: 1,758 words · 7 min read · ~6 pages · Grade level 11.1 · Accepted 2025-09-15 16:05:10
Key Financial Figures
- $750 million — Inc. (the "Company") closed its sale of $750 million aggregate principal amount of its 4.000
- $1,000 million — 600% Notes due 2032 (the "2032 Notes"), $1,000 million aggregate principal amount of its 5.000
- $500 million — % Notes due 2036 (the "2036 Notes") and $500 million aggregate principal amount of its 5.700
- $2,972.7 million — pany received proceeds of approximately $2,972.7 million from the sale of the Notes after deduct
- $400 million — proceeds to repay or redeem all of the $400 million aggregate principal amount of its 5.350
Filing Documents
- d79603d8k.htm (8-K) — 36KB
- d79603dex11.htm (EX-1.1) — 189KB
- d79603dex42.htm (EX-4.2) — 47KB
- d79603dex43.htm (EX-4.3) — 46KB
- d79603dex44.htm (EX-4.4) — 46KB
- d79603dex45.htm (EX-4.5) — 50KB
- d79603dex51.htm (EX-5.1) — 13KB
- d79603dex52.htm (EX-5.2) — 14KB
- g79603dsp051.jpg (GRAPHIC) — 9KB
- g79603g0912040848357.jpg (GRAPHIC) — 2KB
- 0001193125-25-203542.txt ( ) — 676KB
- elv-20250908.xsd (EX-101.SCH) — 3KB
- elv-20250908_lab.xml (EX-101.LAB) — 17KB
- elv-20250908_pre.xml (EX-101.PRE) — 11KB
- d79603d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Exhibit 1.1 Underwriting Agreement, dated as of September 8, 2025, among the Company and BofA Securities, Inc., Deutsche Bank Securities Inc. and Mizuho Securities USA LLC 4.1 Indenture, dated as of November 21, 2017, among the Company and the Bank of New York Mellon Trust Company, N.A. as trustee (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on November 21, 2017) 4.2 Form of the 4.000% Notes due 2028 4.3 Form of the 4.600% Notes due 2032 4.4 Form of the 5.000% Notes due 2036 4.5 Form of the 5.700% Notes due 2055 5.1 Opinion of Hogan Lovells US LLP 5.2 Opinion of Faegre Drinker Biddle & Reath LLP 23.1 Consent of Hogan Lovells US LLP (included in the opinion filed as Exhibit 5.1) 23.2 Consent of Faegre Drinker Biddle & Reath LLP (included in the opinion filed as Exhibit 5.2) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 15, 2025 ELEVANCE HEALTH, INC. By: /s/ Kathleen S. Kiefer Name: Kathleen S. Kiefer Title: Chief Governance Officer & Corporate Secretary